This pilot human trial is designed to evaluate the feasibility of replacing the current non-degradable VAC device wound interface with a NovoSorb product. Key elements of the trial protocol to test the safety and suitability of the NovoSorbTM product will be as follows: • 20 patients randomised with10 using NovoSorbTM and 10 using Granufoam® dressings; • The current standard of care including 3 dressing changes per week will be adopted; • Treatment duration of up to 8 weeks, less if the wound bed is suitable for definitive closure by skin graft; • Disease indication - Sacral pressure sores; and • Single study site (Royal Adelaide Hospital)
The open question is this: If dressings are to be changed three times a week, what therapeutic advantage is expected from using a biodegradable Novosorb dressing?
CZD Price at posting:
6.0¢ Sentiment: Buy Disclosure: Held
